The impact of headache in Europe: principal results of the Eurolight project

The Journal of Headache and Pain

Research Article

Elena Ruiz de la Torre¹  Jessica Barré²  Colette Andrée³  Michel Lantéri-Minet⁴  Jose Miguel Lainez⁵  Zaza Katsarava⁶  Timothy J Steiner⁷  Lars Jacob Stovner⁸  Christian Lampl⁹  Cristina Tassorelli^1,10  Daiva Rastenyte^1,11 

[1] Asociacion Española de Pacientes con Cefalea (AEPAC), Valencia, Spain;Center of Public Health Research, CRP-Santé, Strassen, Luxembourg;Center of Public Health Research, CRP-Santé, Strassen, Luxembourg;Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland;Departement d’Evaluation et Traitement de la Douleur, Centre Hospitalo-Universitaire de Nice, Nice, France;Department of Neurology, Hospital Clinico Universitario, University of Valencia, Valencia, Spain;Department of Neurology, University of Essen, Essen, Germany;Department of Neuroscience, Norwegian University of Science and Technology, Edvard Griegs Gate, NO-7491, Trondheim, Norway;Division of Brain Sciences, Imperial College London, London, UK;Department of Neuroscience, Norwegian University of Science and Technology, Edvard Griegs Gate, NO-7491, Trondheim, Norway;Norwegian National Headache Centre, St Olavs University Hospital, Trondheim, Norway;Headache Medical Center Seilerstaette Linz, Department of Neurogeriatric Medicine and Remobilisation, Hospital of the Sisters of Charity, Linz Seilerstaette 4, 4010, Linz, Austria;Headache Science Centre, C Mondino National Neurological Institute and Department of Brain and Behaviour, University of Pavia, Pavia, Italy;Lithuanian University of Health Sciences, Kaunas, Lithuania;

关键词: Headache;    Migraine;    Impact;    Prevalence;    Europe;    Eurolight project;    Global Campaign against Headache;   

DOI  :  10.1186/1129-2377-15-31

 received in 2014-04-12, accepted in 2014-05-09,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundEuropean data, at least from Western Europe, are relatively good on migraine prevalence but less sound for tension-type headache (TTH) and medication-overuse headache (MOH). Evidence on impact of headache disorders is very limited. Eurolight was a data-gathering exercise primarily to inform health policy in the European Union (EU). This manuscript reports personal impact.MethodsThe study was cross-sectional with modified cluster sampling. Surveys were conducted by structured questionnaire, including diagnostic questions based on ICHD-II and various measures of impact, and are reported from Austria, France, Germany, Italy, Lithuania, Luxembourg, Netherlands, Spain and United Kingdom. Different methods of sampling were used in each. The full methodology is described elsewhere.ResultsQuestionnaires were analysed from 8,271 participants (58% female, mean age 43.4 y). Participation-rates, where calculable, varied from 10.6% to 58.8%. Moderate interest-bias was detected. Unadjusted lifetime prevalence of any headache was 91.3%. Gender-adjusted 1-year prevalences were: any headache 78.6%; migraine 35.3%; TTH 38.2%, headache on ≥15 d/mo 7.2%; probable MOH 3.1%. Personal impact was high, and included ictal symptom burden, interictal burden, cumulative burden and impact on others (partners and children). There was a general gradient of probable MOH > migraine > TTH, and most measures indicated higher impact among females. Lost useful time was substantial: 17.7% of males and 28.0% of females with migraine lost >10% of days; 44.7% of males and 53.7% of females with probable MOH lost >20%.ConclusionsThe common headache disorders have very high personal impact in the EU, with important implications for health policy.

【 授权许可】

CC BY   
© Steiner et al.; licensee Springer. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.